Cipla (CIPLA) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue reached INR 6,957 crore, up 4% year-over-year, with EBITDA margin at 25.6% and PAT at INR 1,298 crore, up 10.2% YoY.

• One India business crossed INR 3,000 crore in quarterly revenue for the first time, now 44% of global revenue.

• North America revenue was $226 million, with Albuterol leading the US MDI market at 19.5% share and new oncology launches.

• Africa and EMU businesses grew 11% and 8% YoY in USD terms, respectively, despite geopolitical headwinds.

• Unaudited consolidated and standalone financial results for the quarter ended 30th June 2025 were approved and released, with statutory auditors providing an unmodified review conclusion.

Financial highlights

• EBITDA margin (excluding other income) stood at 25.6%, flat YoY.

• Gross margin after material cost improved to 68.8%, up 156 bps YoY.

• Profit after tax was INR 1,298 crore, up 10.2% YoY, representing 18.7% of sales.

• R&D investments were INR 432 crore (6.2% of revenue), supporting pipeline development.

• Net cash position at INR 10,379 crore, with total debt (including leases) at INR 459 crore as of June 30.

Outlook and guidance

• FY26 EBITDA margin guidance maintained at 23.5%-24.5%.

• Focus areas: regain growth momentum in India, accelerate US launches, expand South Africa margins, and deepen EMU penetration.

• North America pipeline includes launches of biosimilars and differentiated respiratory assets, with 2-3 peptide assets expected in FY26.

• Continued focus on innovative respiratory and chronic therapies in India, with strategic restructuring to drive triple therapy launches.

• US business targets $1 billion sales by FY27, driven by pipeline launches including Symbicort.